Aequus Provides General Update and Reports Record 2021 Financial Results

[ad_1]

Aequus Pharmaceuticals

Aequus Pharmaceuticals

Also reports Financial Results for the 3 months ended March 31, 2022

VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues from direct product sales and profit share arrangements, today reported financial results for the year ended December 31, 2021 (“Fiscal 2021”) and the three months ended March 31, 2022 (“Q1 2022”), and reports associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

Mr. Janzen commented “Waiting for our auditors to complete their audit of the annual financial statement have been frustrating for both ourselves and our shareholders. The delay was due to a significant number of new information requests from our auditors to our commercial partners. No material weaknesses in Aequus controls or policies were identified as the cause of the delay in filing our financials and we are very grateful to our commercial partners for the significant time they spent with our auditors to complete our annual audit. Now that our Fiscal 2021 and Q1 2022 financial statements have been filed we expect Aequus shares to resume trading on the TSX-V on or before July 8, 2022.”

The year ended December 31, 2021 was the final year of the Sandoz original agreement terms and was the highest gross revenue year in the history of the Company. The first quarter is traditionally our weakest quarter and the first half of 2022 is expected to be a transition period as we adjust to lower Tacrolimus revenues and enter into agreements with partners to add additional products.

“I personally entered into a $2,000,000 loan agreement with the Company last month because I believe in our ability to continue to grow revenues and add new products at Aequus. This loan should allow the Company to bridge Q1 revenue weakness given the amended Sandoz contract terms announced last January.”

On May 9, 2022, the Company was the subject of a failure-to-file cease trade order (“CTO”) issued by the British Columbia Securities Commission (“BCSC”) pending the filing of the Company’s annual audited financial statements, Management disclosure and analysis and Annual Information Form for the 2021 financial year (collectively, the “2021 Annual Disclosure”). The delayed filing of our 2021 Annual Disclosure resulted from delays in our auditor’s obtaining information they needed from third parties, which delayed necessary audit procedures beyond our annual filing deadlines. As a consequence of the CTO, the BCSC suspended trading of the Company’s securities. The audit of the annual financial statements is now complete, and the Company believes it is now current with its continuous disclosure obligations, however, the CTO will remain in place until the BCSC has issued a revocation order. The Company’s management, audit committee and board will discuss actions to prevent this type of issue from happening again.

Balance Sheet highlights

 

 

 

March 31, 2022

December 31, 2021

As at

 

 

(unaudited)

(audited)

ASSETS

 

 

 

 

Current assets

 

 

$2,825,978

$3,592,975

 

 

 

 

 

Convertible promissory note

 

 

 

509,257

 

512,840

Property and equipment

 

 

 

11,032

 

12,765

Right-of-use lease asset, net

 

 

 

199,596

 

229,535

Total assets

 

 

$3,545,863

$4,348,115

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY`

Current liabilities

 

 

$2,584,647

$2,457,068

 

 

 

 

 

CEBA Loan

 

 

 

27,002

 

26,087

Lease liability

 

 

 

42,384

 

75,895

Total liabilities

 

 

 

2,654,033

 

2,559,050

 

 

 

 

 

Shareholders’ Equity

 

 

 

891,830

 

1,789,065

Total liabilities and shareholders’ equity

 

 

$3,545,863

$4,348,115

Key Fiscal 2021 Financial Highlights

For the years ended December 31

 

 

 

 

2021

 

2020

Revenue

 

 

 

 

 

Promotional

 

 

 

$2,610,826

$2,592,613

Product

 

 

 

 

103,872

 

 

 

 

 

 

2,714,698

 

2,592,613

Cost of goods sold

 

 

 

 

25,779

 

 

 

 

 

 

2,688,919

 

2,592,613

 

 

 

 

 

 

Operating expenditures:

 

 

 

 

 

Research and development

 

 

 

 

296,848

 

54,608

Sales and marketing

 

 

 

 

2,190,592

 

1,547,773

General and administration

 

 

 

 

2,023,773

 

2,055,221

 

 

 

 

 

4,511,213

 

3,657,602

 

 

 

 

 

 

Loss before other income (loss)

 

 

 

 

(1,822,294)

 

(1,064,989)

Other income (loss)

 

 

 

 

12,702

 

19,629

Net loss

 

 

 

$(1,809,592)

$(1,045,360)


Key Q1 2022 Unaudited Financial Highlights

 

 

 

 

 

For the three months ended March 31

 

 

 

2022

 

2021

Revenue

 

 

 

 

Promotional

 

 

$262,520

$481,463

Product

 

 

 

39,760

 

10,358

 

 

 

 

302,280

 

491,821

Cost of goods sold

 

 

 

9,781

 

2,613

 

 

 

 

292,499

 

489,208

 

 

 

 

 

Operating expenditures:

 

 

 

 

Research and development

 

 

 

246,107

 

87,898

Sales and marketing

 

 

 

489,132

 

477,830

General and administration

 

 

 

475,828

 

547,116

 

 

 

 

1,211,067

 

1,112,844

 

 

 

 

 

Loss before other income (loss)

 

 

 

(918,568)

 

(623,636)

Other income (loss)

 

 

 

1,682

 

1,978

Net loss

 

 

$(916,886)

$(621,658)


ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

FORWARD-LOOKING STATEMENT DISCLAIMER

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: our ability to continue to grow revenues and add new products; the two million dollar loan allowing us to bridge Q1 revenue decreases given the amended Sandoz contract; the expectation that Q1 2022 is a transition period as we look to add to our product offerings; the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company’s expected revenues; the regulatory approval of its products; and the revocation of the CTO. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; the impact of the coronavirus (COVID-19) on the Company’s operations; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated June 30, 2022, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

CONTACT INFORMATION
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906

[ad_2]

Read More: Aequus Provides General Update and Reports Record 2021 Financial Results

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments